Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Saved in:
| Title: | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens. |
|---|---|
| Authors: | Dai MS; Department of Hematology-Oncology, Tri-Service General Hospital, Taipei, Taiwan., Feng YH; Department of Hematology-Oncology, Chi Mei Medical Center-Yongkang Branch, Tainan, Taiwan., Chen SW; Department of Hematology-Oncology, Chi Mei Medical Center-LiouYing Branch, Tainan, Taiwan., Masuda N; Department of Surgery and Breast Oncology, National Hospital Organization Osaka National Hospital, Osaka, Japan., Yau T; Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong., Chen ST; Department of Surgery, Changhua Christian Hospital, Changhua, Taiwan., Lu YS; Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan., Yap YS; Department of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore., Ang PCS; Department of Medical Oncology, OncoCare Cancer Centre, Singapore, Singapore., Chu SC; Department of Hematology-Oncology, Hualien Tzu Chi Hospital, Hualien, Taiwan., Kwong A; Department of Surgery, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, Hong Kong., Lee KS; Center for Breast Cancer, National Cancer Center, Goyang-si, South Korea., Ow S; Department of Haematology and Oncology, National University Cancer Institute, Singapore, Singapore., Kim SB; Department of Oncology, Asan Medical Center, Seoul, South Korea., Lin J; Department of Hematology-Oncology, Mackay Memorial Hospital, Taipei, Taiwan., Chung HC; Department of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Ngan R; Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, Hong Kong., Kok VC; Division of Medical Oncology, Kuang Tien General Hospital Cancer Center, Taichung, Taiwan., Rau KM; Department of Hematology-Oncology, E-Da Cancer Hospital, Kaohsiung, Taiwan., Sangai T; Department of Breast and Thyroid Surgery, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan., Ng TY; Department of Clinical Oncology, Tuen Mun Hospital, Hong Kong, Hong Kong., Tseng LM; Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan., Bryce R; Puma Biotechnology Inc., Los Angeles, USA., Bebchuk J; Department of Biostatistics, Puma Biotechnology Inc., Los Angeles, USA., Chen MC; Clinical Development and Medical Affairs, CANbridge Pharmaceuticals Inc., Taipei, Taiwan., Hou MF; Division of Breast Oncology and Surgery, Kaohsiung Medical University Chung-Ho Memorial Hospital, No.100, Tzyou 1st Road, Kaohsiung, 807, Taiwan. mifeho@kmu.edu.tw. |
| Source: | Breast cancer research and treatment [Breast Cancer Res Treat] 2021 Oct; Vol. 189 (3), pp. 665-676. Date of Electronic Publication: 2021 Sep 23. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1573-7217 |
|---|---|
| DOI: | 10.1007/s10549-021-06313-5 |
